A database of FDA approved therapeutic peptides and proteins
ID1659 | ThPPIDTh1152 | NameDrotrecogin alfa | Peptide SequenceHeavy Chain: LIDGKMT Full view | Length402 | Functional ClassificationIb | DiseaseInfectious | BrandXigris | CompanyEli Lilly and Company | Physical AppearanceSterile, lyophilized, white to off-white powder | Route of AdministartionIntravenous Infusion | CategoryAntisepsis | TargetCoagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
ID1780 | ThPPIDTh1188 | NameHyaluronidase (Human Recombinant) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseAdjunct therapy | BrandNA | CompanyNA | Physical AppearanceNA | Route of AdministartionNA | CategoryNA | TargetHyaluronan; Transforming growth factor beta-1 |
ID1805 | ThPPIDTh1199 | NameRamucirumab | Peptide Sequenceramucirumab|Homo sap Full view | Length909 | Functional ClassificationIIIc | DiseaseCancer | BrandCyramza | CompanyEli Lilly and Company | Physical AppearanceSolution | Route of AdministartionIntravenous | CategoryAntineoplastic and Immunomodulating Agents | TargetVascular endothelial growth factor receptor 2 |
ID1821 | ThPPIDTh1212 | NameInsulin Pork | Peptide SequenceA chain GIVEQCCTSICS Full view | Length68 | Functional ClassificationIa | DiseaseMetabolic Disorders | BrandIletin II | CompanyLilly | Physical Appearancesterile suspension | Route of AdministartionSubcutaneous | CategoryHypoglycemic Agents, Antidiabetic Agents | TargetInsulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |
ID1831 | ThPPIDTh1221 | NameC1 Esterase Inhibitor (Recombinant) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIa | DiseaseCardiac Disorders | BrandRuconest | CompanyTjoapack Netherlands Bv | Physical AppearancePowder and liquid for solution | Route of AdministartionIntravenous | CategoryBlood and Blood Forming Organs | TargetComplement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator |
ID1844 | ThPPIDTh1232 | NameLenograstim | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseImmunological Disorders | BrandGranocyte | CompanyNA | Physical AppearanceSolid | Route of AdministartionSubcutaneous or Intravenous | CategoryAntineoplastic and Immunomodulating Agents | TargetGranulocyte colony-stimulating factor receptor |
ID1851 | ThPPIDTh1238 | NameSusoctocog alfa | Peptide SequenceAIRRYYLGAVELSWDYRQSE Full view | Length1448 | Functional ClassificationIb | DiseaseHematological Disorders | BrandObizur | CompanyNA | Physical AppearancePowder and solvent for solution for injection. | Route of AdministartionIntravenous | CategoryBlood coagulation factors, Antihaemorrhagics | Targetvon Willebrand factor |
ID1852 | ThPPIDTh1239 | NameThrombomodulin Alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandRecomodulin (in Japan only) | CompanyAsahi Kasei Pharma Corp | Physical Appearancelyophilized powder for solution | Route of AdministartionIntravenous | CategoryAnticoagulant agent, Antiplatelet agent | TargetProthrombin, Coagulation factor V |